Anti-payload Antibodies
Antibody-Drug Conjugates (ADCs) are composed of three parts: a monoclonal antibody, a linker, and a cytotoxic payload. They combine the advantages of both antibody-based biologics and traditional chemotherapeutics to achieve precise and effective killing of cancer cells, making them one of the hottest areas in anticancer drug development. The antibody in an ADC acts as a “navigator” with targeting capabilities. It specifically binds to antigens on the surface of tumor cells and is then internalized, delivering the cytotoxic payload into the cells to exert its toxic effects. The linker serves as a bridge between the antibody and the drug, controlling the release of the payload within cancer cells. The cytotoxic payload, also referred to as the ADC payload or warhead, functions as the “bullet” of the ADC. Its activity and physicochemical properties directly impact the anti-tumor efficacy of the ADC.
Unlike traditional small-molecule drugs or monoclonal antibodies alone, ADCs contain both large and small molecule components. Therefore, bioanalysis of ADCs requires a combination of analytical methods and platforms. This includes ligand-binding assays for the antibody (large molecule) component and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the small molecule payload.
Anti-payload antibodies, as the name suggests, are antibodies that specifically recognize and bind to the small molecule payloads in ADCs. These antibodies play a critical role in ADC immunogenicity analysis. DIMA BIOTECH is committed to advancing ADC research by providing researchers with the necessary tools and technical services to better define and support precision medicine. Currently, DIMA has developed multiple anti-payload antibodies, including anti-MMAE, anti-Dxd, and anti-SN38 antibodies. These antibodies have demonstrated remarkable performance in a variety of drug testing scenarios and hold great potential in accelerating ADC development.
Application Scenarios
- Pharmacokinetic (PK) analysis of ADCs in plasma/serum
- Binding affinity measurement
- Drug-to-Antibody Ratio (DAR) analysis
- Assessment of ADC therapeutic efficacy
DIMA's Features
- High Specificity: Validated by ELISA-based activity assays, specifically binds to the target small molecule.
- Customizable Formats: Available in various formats, including unlabeled (naked) antibodies and biotin-labeled versions.
- Rapid Custom Development: Powered by DIMA’s innovative monoclonal antibody platform, enabling fast development and production of novel anti-payload antibodies.
